CAR-T therapy study for rebuilding HIV immune defenses
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This early-stage study tests whether CAR-T cells can help rebuild the immune system’s ability to fight HIV. You may be a candidate if your HIV is well controlled on standard treatment and you don’t have certain serious infections or organ problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HIV infection.
- You have been taking cART (standard HIV medicines) for more than 12 months.
- Your HIV viral load is very low (less than 50 copies/mL) and your CD4 count is above 350.
- You do not have serious problems with your heart, liver, or kidneys.
- You can understand the study, agree to participate, and sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of immune treatment (CAR-T cells) designed to calm overactive immune disease. It may help by aiming the therapy at immune cells involved in B-cell activity, but it has strict health and safety requirements.
This early-phase study tests whether CAR-T cells (immune cells modified to recognize HIV) can help control HIV. You may be asked to briefly pause HIV medicines to see how well the treatment controls the virus.
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
This trial tests whether CAR-T cells can help control HIV without daily antivirals. It is for people with well-controlled HIV who want to explore a potential functional cure.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Hear when a new HIV/AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.